Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diffuse gliomas can be separated in astrocytoma and oligodendroglioma based on IDH1/2, ATRX, and TP53 mutational status.
|
31714292 |
2020 |
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patient KK was a 68-yr-old female who was found to have a large, left-sided insular mass that was shown to be an oligodendroglioma WHO grade II, positive for codeletion 1p/19q and IDH1 mutant on biopsy.
|
31058967 |
2020 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gliomas were assigned to one of the three molecular groups: Group O (IDH-mutant, 1p/19q co-deleted oligodendrogliomas, n = 95), Group A (IDH-mutant, ATRX inactivated astrocytomas, n = 175) and Group G (IDH wild-type, GBM-like, n = 46).
|
30536195 |
2019 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant.
|
30710203 |
2019 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The DSC-MRI procedure may provide insight into the IDH1/2 mutation and ATRX expression status and MGMT methylation profile of diffuse glioma; however, taking integrated oligodendroglioma into account limits the diagnostic performance of rCBV in non-invasively predicting the molecular subtype.
|
29468261 |
2019 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The reported two cases were initially diagnosed as oligodendroglioma with 1p/19q-codeletion and mutation of <i>isocitrate dehydrogenase 1 (IDH1)</i>-R132H.
|
31508376 |
2019 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
<i>TERT</i> promoter mutations are selectively observed among 1p/19q-codeleted oligodendrogliomas and isocitrate dehydrogenase gene- <i>(IDH-)</i> wildtype glioblastoma (GBM).
|
29693015 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We excluded glioblastoma-like tumors (7a10d subgroup) and derived a gene expression signature distinguishing histologically classified oligodendrogliomas with concurrent 1p/19q co-deletion and IDH mutation (1p/19q subgroup) from those with predominant IDH mutation alone (IDHme subgroup).
|
29631562 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, identification of a common IDH1 mutation in enchondroma and oligodendroglioma-matched pair specimens supports the hypothesis that IDH1/2 mosaicism initiates tumorigenesis.
|
29224049 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
36 (57%) had oligodendroglioma and 27 astrocytoma.IDH-1 mutation was present in 53 (84%).
|
30292978 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Most tumors have a missense mutation for IDH1 combined with 1p19q codeletion in oligodendrogliomas or ATRX/TP53 mutations in astrocytomas.
|
29027701 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second.
|
29077933 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Trisomy of chromosome 7 in IDH mutated astrocytoma and PTEN mutations in IDH mutated oligodendroglioma are potential markers of poor prognosis, but require confirmation in larger series.
|
29663171 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Secondly, when analyzed in molecular subgroups, we were similarly unable to detect a significant PFS or OS benefit in IDH MT/codel subgroup (N = 269; HR 1.47; 95% CI 0.92-2.34; P = 0.11 and HR 1.54; 95% CI 0.78-3.05; P = 0.21, respectively), oligodendroglioma with IDH MT/codel subgroup (N = 233; HR 1.33; 95% CI 0.79-2.21; P = 0.28 and HR 1.16; 95% CI 0.53-2.54; P = 0.70, respectively) or other relevant subgroups.
|
30206763 |
2018 |
Well Differentiated Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the 2016 WHO classification, the diagnosis of oligodendroglioma has been restricted to IDH mutated, 1p19q codeleted tumors (IDHmut-codel).
|
29186201 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The 25th, 50th, 75th, and 90th percentiles of MK and average MK showed significant differences between IDH1/2<sub>wild-type</sub> gliomas, IDH1/2<sub>mutated</sub> gliomas, and oligodendrogliomas with chromosome 1p/19q loss of heterozygosity and IDH1/2<sub>mutation</sub> (p<0.001).
|
28987669 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Distinct spectral profiles were observed for lesions with IDH-mutated genotypes, between astrocytoma and oligodendroglioma histologies, as well as for tumors that had undergone MP.
|
28327577 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sixty-five patients with 2007 histological designations (astrocytomas and oligodendrogliomas), 1p/19q status (+ = intact/- = co-deleted), and IDH1 mutation status (MUT/WT) were included in this study.
|
28547590 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Triple-positive (IDH1 and TERT mutation with 1p19q codeletion) glioma tended to be oligodendroglioma present with much better clinical outcome compared to TERT mutation only group who is glioblastoma inclined (median overall survival 39 months VS 18 months).
|
28915860 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Non-canonical IDH mutations were identified in 13/52 (25.0%) grade II gliomas (astrocytomas: 8/31, 25.8%; oligodendrogliomas: 5/21, 23.8%) and in 5/40 (12.5%) grade III gliomas (astrocytomas: 3/25, 12.0%; oligodendrogliomas: 2/15, 13.3%).
|
28748342 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study we searched for FGFR1-ITD by droplet digital PCR (DDPCR™) and for FGFR1 point mutations by HRM-sequencing in a series of formalin-fixed paraffin-embedded (FFPE) LGNTs including 12 DNT, 2 oligodendrogliomas lacking IDH mutation and 1p/19q co- deletion (pediatric-type oligodendrogliomas; PTOs), 3 pediatric diffuse astrocytomas (PDAs), 14 gangliogliomas (GGs) and 5 pilocytic astrocytomas (PAs).
|
27791984 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The NGS approach was effective in reclassifying 36 oligoastrocytomas as 30 astrocytomas (20 IDH1/2 mutant and 10 IDH1/2 wild type) and 6 oligodendrogliomas, and 1 oligodendroglioma as an astrocytoma (IDH1/2 mutant).
|
28042970 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In patients with ODG (Group 1), mutant IDH and TERTp did not have prognostic value because these mutations were universally present.
|
28851427 |
2017 |
Well Differentiated Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IDH1-R132H and 1p19q loss were found only in 12 out of the 13 oligodendrogliomas (P<0.0001).
|
27389560 |
2016 |